Discovery of Clinical Candidate (5-(3-(4-Chlorophenoxy)prop-1-yn-1-yl)-3-hydroxypicolinoyl)glycine, an Orally Bioavailable Prolyl Hydroxylase Inhibitor for the Treatment of Anemia
作者:Xiaojin Zhang、Yonghua Lei、Tianhan Hu、Yue Wu、Zhihong Li、Zhensheng Jiang、Changyong Yang、Lianshan Zhang、Qidong You
DOI:10.1021/acs.jmedchem.0c01161
日期:2020.9.10
and discovery of a new series of (5-alkynyl-3-hydroxypicolinoyl)glycine inhibitors of prolyl hydroxylase (PHD) are described. These compounds showed potent in vitro inhibitory activity toward PHD2 in a fluorescence polarization-based assay. Remarkably, oral administration of 17, with an IC50 of 64.2 nM toward PHD2, was found to stabilize HIF-α, elevate erythropoietin (EPO), and alleviate anemia in a
设计和发现了一系列新的脯氨酰羟化酶(PHD)的(5-炔基-3-羟基吡啶啉)甘氨酸抑制剂。这些化合物在基于荧光偏振的测定中显示出对PHD2的有效体外抑制活性。值得注意的是,口服给药17,与IC 50 64.2 nM的朝向PHD2的,被发现以稳定HIF-α,ELEVATE促红细胞生成素(EPO),和减轻贫血在顺铂诱导的贫血的小鼠模型以25毫克的口服剂量/公斤。大鼠和狗的研究表明17具有良好的药代动力学特性,口服生物利用度分别为55.7和54.0%,即使在这些动物中以200 mg / kg的高剂量使用时,也显示出极好的安全性。根据这些结果,17 目前正在I期贫血的临床试验中进行评估。